pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 30·1 min read
save

Ipsen says €2 billion cash reserves give it firepower for more M&A

Jul 30, 2026·read at Endpoints ↗DealPositive

Ipsen's CFO Aymeric Le Chatelier said the company ended June with €2 billion in cash, which it describes as "firepower" for acquisitions.

The cash position gives the French biotech firm flexibility to pursue additional M&A opportunities, according to the executive.

The statement signals that Ipsen may look to expand its portfolio in the near term, though no specific targets were disclosed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Ipsen has 'firepower' for more deals with €2B war chest”

read at Endpoints ↗
86 words · retrieved Jul 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
IPSEN7

related stories

  • Sep 30PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalBioPharma Dive
  • Sep 28FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseaseBioSpace
  • Sep 239 pharma leaders sound ‘alarm bells’ on biotech’s decline in EuropeBioPharma Dive
  • Sep 21STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and moreSTAT
  • Sep 1Roche inks $1.53B deal for Simcere’s B-cell-targeting antibodyFierce Biotech